Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
NkAu7vQnYRWjukTT
